21. ESC Committee. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Executive summary. Third Joint European and Other Societies Task Force on Cardiovascular Disease Prevention in Clinical Practice / ESC Committee // Eur. Heart J. - 2003. - Vol. 24, № 17. - P. 1601-1610.

22. Fontana V. An update on the pharmacogenetics of treating hypertension [Електронний ресурс] / V. Fontana, M.R. Luizon, V.C. Sandrim // J. Hum. Hypertens. - 2014. - Режим доступу до журналу: http://www.researchgate.net/ publication/267735322.

23. Mediators of sympathetic activation in metabolic syndrome obesity / N.E. Straznicky, N. Eikelis, E.A. Lambert [et al.] // Current Hypertension Reports. - 2008. - Vol. 10, № 6. - P. 440-447.

24. Pathophysiology of resistant hypertension: the role of sympathetic nervous system [Електронний ресурс] / C. Tsioufis, A. Kordalis, D. Flessas [et al.] // International Journal of Hypertension. - 2011. - Режим доступу до журналу: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034926/pdf/IJHT2011-642416.pdf - Назва з екрану.

25. Biaggioni I. Sympathetic control of the circulation in hypertension: lessons from autonomic disorders / I. Biaggioni // Curr. Opin. Nephrol. Hypertens. - 2003. - № 12(2). - Р. 175-80.

26. DiBona G.F. Translational medicine: the antihypertensive effect of renal denervation / G.F. DiBona, M. Esler // Am. J. Physiol. Regul. Integr. Comp. Physiol. - 2010. - № 298. - Р. 245-253.

27. Esler M. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension / M. Esler, E. Lambert, М. Schlaich // J. Appl. Physiol. - 2010. - № 109. - Р. 1996-1998.

28. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension / G. Grassi, B.M. Cattaneo, G. Seravalle [et al.] // Hypertension. - 1998. - № 31. - P. 68-72.

29. Straznicky N.E. Neuroadrenergic dysfunction in obesity: an overview of the effects of weight loss / N.E. Straznicky, G.W. Lambert, E.A. Lambert // Curr. Opin. Lipidol. - 2010. - № 21(1). - P. 21-30.

30. Relationship between central sympathetic activity and stages of human hypertension / P.A. Smith, L.N. Graham, A.F. Mackintosh [et al.] // Am. J. Hypertens. - 2004. - № 17. - P. 217-222.

31. Neurogenic abnormalities in masked hypertension / G. Grassi, G. Seravalle, F. Quarti Trevano [et al.] // Hypertension. . - 2007. - № 50. - P. 537-542.

32. Hart E.C. Sympathetic neural mechanisms in human blood pressure regulation / E.C. Hart, N. Charkoudian // Curr. Hypertens. Rep. - 2011. - № 13(3). - P. 237-243.

33. Oliva R.V. Sympathetic activation in resistant hypertension: theory and therapy / R.V. Oliva, G.L. Bakris // Semin. Nephrol. - 2014. - № 34(5). - P. 550-559.

34. Hypertension and obesity / A. Aneja, F. El-Atat, S.I. McFarlane [et al.] // Recent. Progr. Horm. Res. - 2004. - № 59. - P. 169-205.

35. The sympathetic nervous system and the metabolic syndrome / G. Mancia, P. Bousquet, J.L. Elghozi [et al.] // J. Hypertens. - 2007. - № 25. - P. 909-920.

36. Tentolouris N. Sympathetic system activity in obesity and metabolic syndrome / N. Tentolouris, S. Liatis, N. Katsilambros // Ann. N. Y. Acad. Sci. - 2006. - № 1083. - P. 129-152.

37. Ожирение и артериальная гипертензия. Часть I: снижение веса и нормализация артериального давления / С.В. Недогода, И.Н. Барыкина, У.А. Брель [и др.] // Кардиоваскулярная терапия и профилактика. - 2008. - № 5. - С. 105-115.

38. Долинна О.В. Стан дофамінового обміну та його корекція у хворих з артеріальною гіпертензією та супутнім ожирінням: автореф. дис. на здобуття наук. ступеня канд. мед. наук: спец. 14.01.02 "Внутрішні хвороби" / Долинна Ольга Віталіївна; Нац. мед. ун-т ім. О.О. Богомольця. - К., 2004. - 19 с.

39. The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure Study / S. Julius, K. Jamerson, A. Mejja [et al.] // JAMA. - 1990. - № 264. - Р. 354-358.

40. Effect of central and peripheral obesity body fat distribution on sympathetic and baroreflex function in obese normotensives / G. Grassi, R. Dell'Oro, A. Facchini [et al.] // J. Hypertens. - 2004. - № 22. - Р. 2363-2369.

41. Hypertension: physiology and pathophysiology / J.E. Hall, J.P. Granger, J.M. do Carmo [et al.] // Compr. Physiol. - 2012. - № 2(4). - Р. 2393-2442.

42. Mechanisms of obesity-associated cardiovascular and renal disease / J.E. Hall, E.D. Crook, D.W. Jones [et al.] // Am. J. Med. Sci. - 2002. - Vol. 3, № 324. - P. 127-137.

43. Davy K.P. Sympathetic nervous system behavior in human obesity / K.P. Davy, J.S. Orr // Neurosci. Biobehav. Rev. - 2009. - № 33. - Р. 116-124.

44. Mechanisms of sympathetic activation in obesity-related hypertension / M. Esler, N. Straznicky, N. Eikelis [et al.] // Hypertension. - 2006. - № 48. - Р. 787-796.

45. Lansberg L. Insulin-madiated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) / L. Lansberg // J. Hypertens. - 2001. - Vol .19, № 3. - P. 523-528.

46. Pathways from obesity to hypertension: from the perspective of a vicious triangle / J.P. Montani, V. Antic, Z. Yang [et al.] // Int. J. Obesity. - 2002. - № 26. - P. 28-38.

47. Bloomgarden Z.T. Obesity, hypertension, and insulin resistance / Z.T. Bloomgarden // Diabetes Care. - 2002. - № 25. - P. 2088-2097.

48. Kuo J.J. Chronic cardiovascular and renal actions of leptin during hyperinsulinemia / J.J. Kuo, O.B. Jones, J.E. Hall // Am. J. Physiol. Regul. Integr. Comp. Physiol. - 2003. - Vol. 284, № 4. - P. 1037-1042.

49. Comprehensive Hypertension / J. E. Нall, A. A. da Silva, E. Brandon [et al.] // Elsevier Science Publishing Co., Inc., New York. - 2007. - Р. 447-468.

50. The role of the sympathetic nervous system in obesity-related hypertension / A.A. da Silva, J. do Carmo, J. Dubinion [et al.] // Curr. Hypertens. Rep. - 2009. - Vol. 11, № 3. - P. 206-211.

51. Chronic kidney disease, obesity, and hypertension: the role of leptin and adiponectin [Електронний ресурс] / M. Tesauro, A. Mascali, O. Franzese [et al.] // Int. J. Hypertens. - 2012. - Режим доступу до журналу: http://www.hindawi.com/journals/ijht/2012/943605/ - Назва з екрану.

52. Бутрова С.А. Современные аспекты терапии ожирения / С.А. Бутрова, М.А. Берковская // Поликлиника. - 2012. - № 5. - С. 24-26.

53. Kalil G.Z. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications / G.Z. Kalil, W.G. Haynes // Hypertens. Res. - 2012. - № 35(1). - P. 4-16.

54. da Silva A. A. Role of leptin and central nervous system melanocortins in obesity hypertension / A. A. da Silva, J. M. do Carmo, J.E. Hall // Curr. Opin. Nephrol. Hypertens. - 2013. - № 22(2). - P. 135-140.

55. Obesity-related hypertension: possible pathophysiological mechanisms / I. Vanмиkovб, L. Maletнnskб , M. Behuliak [et al.] // J. Endocrinol. - 2014. - № 223(3). - P. 63-78.

56. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension / C. de Haro Moraes, V.N Figueiredo, A.P. de Faria [et al.] // J. Hum. Hypertens. - 2013. - № 27(4). - P. 225-230

57. Leptin and aldosterone in sympathetic activity in resistant hypertension with or without type 2 diabetes / L. Boer-Martins, V.N. Figueiredo, C. Demacq [et al.] // Arq. Bras. Cardiol. - 2012. - № 99(1). - P. 642-648.

58. Chronic cardiovascular and renal actions of leptin-role of adrenergic activity / M. Carlyle, O.B. Jones, J.J. Kuo [et al] // Hypertension. - 2002. - № 39 - Р. 496-501.

59. Kuo J.J. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin / J.J. Kuo, O.B. Jones, J.E. Hall // Hypertension. - 2001. - № 37. - Р. 670-676.

60. Ozata M. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects / M. Ozata, I.C. Ozdemir, J. Licinio // J. Clin. Endocrinol. Metab. - 1999. - № 10. - Р. 3686-3695.

61. Serazin V. Human adipose angiotensinogen gene expression and secretion are stimulated by cyclic AMP via increased DNA cyclic AMP responsive element binding activity / V. Serazin, E. Dos Santos, M. Morot [et al.] // Endocrine. - 2004. - № 25. - P. 97-104.

62. Cassis L.A. Role of angiotensin II in brown adipose thermogenesis during cold acclimation / L.A. Cassis // Am. J. Physiol. Endocrinol. Metab. - 1993. - № 265. - P. 860-865.

63. Central angiotensin II has catabolic action at white and brown adipose tissue / A.D. de Kloet, E.G. Krause, K.A. Scott [et al.] // Am. J. Physiol. Endocrinol. Metab. - 2011. - № 301(6). - P. 1081-1091.

64. Баранов В.С. Полиморфизм генов, экогенетические болезни и генетический паспорт / В.С. Баранов // Экологическая генетика. - 2011. - № IX(3). - С. 13-14.

65. в1 and в2 adrenergic receptor polymorphisms: their impact on cardiovascular physiology, disease states, and response to therapeutic agents / A. Namath, C. Chenb, R. Agrawal [et al.] // J. Crit. Care. - 2007. - Vol. 26, № 1. - Р. 2-9.

66. Johnson J.A. Pharmacogenetics and cardiovascular disease-implications for personalized medicine / J.A. Johnson, L.H. Cavallari // Pharmacol. Rev. - 2013. -№ 65(3). - P. 987-1009.

67. Muszkat M. Pharmacogenetics and response to beta-adrenergic receptor antagonists in heart failure / M. Muszkat, C.M. Stein // Clin. Pharmacol. Ther. - 2005. - Vol. 77, № 3. - P. 123-126.

68. The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response / K.M. Giacomini, C.M. Brett, R. B. Altman [et al.] // Clin. Pharm. Ther. - 2007. - № 81. - P. 328-345.

69. Jonson J.A. Hypertension pharmacogenomics: current status and future directions / J.A. Jonson, S.T. Turner // Curr. Opin. Mol. Ther. - 2005. - № 7. - P. 218-225.

70. Arnett D.K. Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance / D.K. Arnett, S.A. Claas // Pharmacogenomics. - 2009. - № 10(8). - P. 1295-1307.

71. Davis B.R. Antihypertensive therapy, the alpha-adduct polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study / B.R. Davis // Pharmacogenomics J. - 2007. - № 7. - P. 112-122.

72. Impact of GPCRs in clinical medicine: genetic variants and drug targets / P.A. Insel, C.M. Tang, I. Hahntow [et al.] // Biochim. Biophys. Acta. - 2007. - № 1768. - P. 994-1005.

73. Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins / M.C. Hendriks-Balk, S.L. Peters, M.C. Michel [et al.] // Eur. J. Pharmacol. - 2008. - № 585. - P. 278-291.

74. G protein-coupled receptor accessory proteins and signaling: pharmacogenomic insights / M.D. Thompson, D.E. Cole, P.A. Jose [et al.] // Methods. Mol. Biol. - 2014. - № 1175. - P. 121-152.

75. Association analyses of adrenergic receptor polymorphism with obesity and metabolic alteration / J.J. Lima, H. Feng, L. Duckworth [et al.] // Metabolism. - 2007. - Vol. 56, № 6. - P. 757-765.

76. Genetic polymorphisms of human beta-adrenergic receptor genes and their association with obesity / Z.Q. Liu, W. Mo, Q. Huang [et al.] // Zhong Nan Da Xue Xue Bao Yi Xue Ban. - 2007. - Vol. 32, № 3. - P. 359-367.

77. Frishman W.H. в-Adrenergic blockade in cardiovascular disease / W.H. Frishman // J. Cardiovasc. Pharmacol. Ther. - 2013. - № 18(4). - P. 310-319.

78. Ferguson S.S. в-adrenoceptors as molecular targets in the treatment of hypertension / S.S. Ferguson, R.D. Feldman // Can. J. Cardiol. - 2014. - № 30. - P. 3-8.

79. Частота поліморфізму генів ангіотензинперетворювального фементу (I/D), рецептора ангіотензину ІІ першого типу (А 1166С), ендотеліальної NO-синтази (Т 894G), рецептора PPAR-г2 (Pro12Ala), в1_адренорецептора (Arg389Gly) у хворих на артеріальну гіпертензію у західно-українській популяції (Буковина) [Електронний ресурс] / Л.П. Сидорчук, К.М. Амосова, Р.А. Волков [та ін.]. - Режим доступу до журналу: www.nbuv.gov.ua/portal/chem_biol/Apagki/V_16/346-361.pdf - Назва з екрану.

80. Рудык Ю.С. Влияние полиморфизма генов адренорецепторов на развитие сердечно-сосудистой патологии и эффективности в_aдреноблокаторов [Електронний ресурс] / Ю.С. Рудык, Н.А. Кравченко, С.В. Виноградова // Практическая ангиология. - 2008. - № 2 (13) - Режим доступу до журналу: http://angiology.com.ua/article/131.html

81. Я-Adrenoceptor polymorphisms / K. Leineweber, R. Bьscher, H. Bruck [et al.] // Naunyn-Schmiedeberg's Archives of Pharmacology. - 2004. - Vol. 369, № 1. - P. 1-22.

82. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor // D.A. Mason, J.D. Moore, S.A. Green [et al.] // J. Biol. Chem. - 1999. - Vol. 274, № 18. - P. 12670-12674.

83. Small K.M. Pharmacology and physiology of human adrenergic receptor polymorphisms / K.M. Small, D.W. McGraw, S.B. Liggett // Annu. Rev. Pharmacol. Toxicol. - 2003. - № 43. - P. 381-411.

84. Ковалева О.Н. Влияние полиморфизма генов адренорецепторов на развитие ожирения и метаболических нарушений (обзор литературы) / О.Н. Ковалева, С.В. Виноградова, Н.А. Кравченко // Журн. АМН України. - 2008. - т. 14, № 3. - С. 450-469.

85. Variants in the human beta1-, beta2-, beta3- adrenergic receptor genes are not associated with morbid obesity in children and adolescents / J. Tafel, I. Branscheid, B. Skwarna [et al.] // Diabetes. Obes. Metab. - 2004. - № 6. - P. 452-455.

86. Удовиченко М.М. Частота встречаемости полиморфизма гена в 1_адренорецепторов у пациентов с хронической сердечной недостаточностью в зависимости от нарушений углеводного обмена / М.М. Удовиченко // Український терапевтичний журнал. - 2011. - № 1. - С. 28-32.

87. Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study / S.G. Terra, S.P. McGorrey, R. Wu [et al.] // Int. J. Obes. (Lond). - 2005. - Vol. 29, № 7. - P. 746-754.

88. Association of GNAS1 gene variant with hypertension depending on smoking status / M. Abe, J. Nakura, M. Yamamoto [et al.] // Hypertehsion. - 2002. - № 40. - P. 8-14.

89. Polymorphisms of the b1-adrenergic receptor gene are associated with essential hypertension in Chinese / Y. Peng., H. Xue, L. Luo [et al.] // Clin. Chem. Lab. Med. - 2009. - Vol.47. - №10. - Р.1227-1231.

90. Masuo K. Relationships of adrenoceptor polymorphisms with obesity [Електронний ресурс] / K. Masuo, G.W. Lambert // J. Obes. - 2011. - Режим доступу до журналу: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092628/pdf/JOBES2011-609485.pdf.

91. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study / Y. Gong [et al.] // Circ. Cardiovasc. Genet. - 2012. - №5. - Р. 686-691.

92. Polymorphism in the в1-adrenergic receptor gene and hypertension / K. Bengtsson, O. Melander, M. Orho-Melander [et al.] // Circulation. - 2001. - Vol. 104, № 2. - P. 187-190.

93. Удовиченко М.М. Особливості перебігу серцевої недостатності у хворих на цукровий діабет 2-го типу залежно від поліморфізму гена бета 1-адренорецепторів: автореферат дис. ... канд. мед. наук: 14.01.02-внутрішні хвороби / М.М. Удовиченко; Харк. нац. мед. ун-т. - Х., 2012. - 20 с.

94. Effects of polymorphisms in beta 1-adrenoceptor and б-subunit of G protein on heart rate and blood pressure during exercise test. The Finnish Cardiovascular Study / Т. Nieminen, T. Lehtimдki, J. Laiho [et al.] // J. Applied. Physiology. - 2006. - Vol. 100, № 2. - Р. 507-511.

95. Нарушения ритма сердца, артериальная гипертензия и генетический полиморфизм адренорецепторов и рецепторов дофамина у пациентов с хроническим алкоголизмом: есть ли взаимосвязь? / А.С. Аксельрод, Н.И. Иванкова, А.О. Кибитов [и др.] // Кардиология и сердечно-сосудистая хирургия. - 2010. - № 2. - С. 72-75.

96. А common bold beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to bold beta-blockade / G. G. Sofowora, V. Dishy, M. Muszkat [et al.] // Clin. Pharm. Ther. - 2003. - №73. - Р. 366-371.

97. Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics / A.L. Beitelshees, I. Zineh, H.N. Yarandi [et al.] // Pharmacogenomics J. - 2006. - Vol.6 - № 3. - Р. 174-178.

98. Вold beta1 adrenergic receptor polymorphisms and antihypertensive response to metoprolol / J.A. Johnson, I. Zineh, B.J. Puckett [et al.] // Clin. Pharm. Ther. - 2003. - № 74. - Р. 44-52.

99. Association of the Gsб gene with essential hypertension and response to в-blockade / H. Jia, A.D. Hingorani, P. Sharma [et al.] // Hypertension. - 1999. - № 34. - P. 8-34.

100. The GNAS 393 T>C Polymorphism and the Blood Pressure Response Immediately Following Aerobic Exercise Among Men with Elevated Blood Pressure / L.S. Pescatello, B.E. Blancharda, G.J. Tsongalisd [et al.] // Vascular Disease Prevention. - 2009. - № 6. - P. 56-64.

101. Association of the GNAS1 gene variant with hypertension is dependent on alcohol consumption / Y. Chen, J. Nakura, J.J. Jin [et al.] // Hypertens. Res. - 2003. - № 26. - P. 439-444.

102. Association of a GNAS1 gene variant with hypertension and diabetes mellitus / M. Yamamoto, M. Abe, J.J. Jin [et al.] // Hypertens. Res. - 2004. - № 27. - P. 919-924.

103. Renal sympathetic nerve ablation for the treatment of uncontrolled hypertension / M.P. Schlaich, P.A. Sobotka, H. Krum [et al.] // N. Engl. J. Med. - 2009. - № 361. - Р. 932-934.

104. The Arg 389Gly beta1-adrenoreceptor polymorphism and catecholamine effects on plasma-renin activity / H. Bruck, K. Leineweber, T. Temme [et al.] // J. Am. Coll. Cardiol. - 2005. - № 46(11). - P. 2111-2115.

105. Effect of specific ADRв1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial [Електронний ресурс] / M. Petersen, J. T. Andersen, E. Jimenez-Solem [et al.] // Pharmacogenetics and Genomics. - 2012. - Режим доступу до журналу: http://www.cpnc.dk/efff.pdf

106. Eikelis N. Нейробиология ожирения человека / N. Eikelis, M. Esler // Обзоры клинической кардиологии (международный медицинский бюллетень). - 2006. - № 4. - С. 2-13.

107. Sympathetic nervous activation in obesity and the metabolic syndrome - causes, consequences and therapeutic implications / G.W. Lambert, N.E. Straznicky, E.A. Lambert [et al.] // Pharmacology and Therapeutics. - 2010. - Vol. 126, № 2. - Р. 159-172.

108. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension / L. Landsberg, L.J. Aronne, L.J. Beilin [et al.] // Obesity (Silver Spring). - 2013. - № 21(1) - P. 8-24.

109. Famalial obesity, sympathetic activation and blood pressure level / K. Masuo, H. Mikami, T. Ogihara [et al.] // Blood pressure. - 2001. - Vol. 10, № 4. - P. 199-204.

110. Cui J. Genes and family environment explain correlations between blood pressure and body mass index / J. Cui, J.L. Hopper, S.B. Harrap // Hypertension. - Vol. 40, № 1. - P. 7-12.

111. Dahlman I. Obesity and polymorphisms in genes regulating human adipose tissue / I. Dahlman, P. Arner // Int. J. of Obesity. - 2001. - № 25. - P. 1629-1641.

112. Лифтиев Р.Б. Роль пищевого поведения в формировании избыточной массы тела и ожирения взрослого населения г. Баку / Р.Б. Лифтиев, А.А. Агаев // Международный медицинский журнал. - 2011. - № 2. - С. 65-68.

113. Farooqi I.S. Genetic factors in human obesity / I.S. Farooqi, S. O'Rahilly // Obesity Reviews. - 2007. - Vol. 8, № 1. - P. 37-40.

114. Eisenach J.H. в-adrenoceptor gene variation and intermediate physiological traits: prediction of distant phenotype / J.H. Eisenach, E.D. Wittwer // Experimental Physiology. - 2010. - Vol. 95, № 7. - P. 757-764.

115. Mutations in the beta1 adrenergic receptor gene and massive obesity in Japanese / Y. Ohshiro, M. Hayashi, K. Yabiku [et al.] // Diabetes. Res. Clin. Pract. - 2008. - Vol. 80, № 2. - Р. 213-217.

116. Attenuation of hemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension / M. Valentini, S. Julius, P. Palatini [et al.] // Journal of Hypertension. - 2004. - Vol. 22, № 10. - P. 1999-2006.

117. Direct evidence for tonic sympathetic support of resting metabolic rate in healthy adult humans / M.B. Monroe, D.R. Seals, L.F. Shapiro [et al.] // Am. J. Of Physiol. - 2011. - Vol. 280, № 5. - P. 740-744.

118. Marti A. Interaction between genes and lifestyle factors on obesity / A. Marti, M.A. Martinez-Gonzбlez, J. A. Martinez // Proceedings of the Nutrition Society. - 2008. - № 67. - Р. 1-8.

119. Farooqi S. Obesity genes - it's all about the parents / S. Farooqi // Cell. Metab. - 2009. - № 9. - P. 487-488.

120. Association between obesity and a polymorphism in the beta(1)- adrenoreceptor gene (Gly389Arg ADRв1) in Caucasian women / I.J. Dionne, M.J. Garant, A.A. Nolan [et al.] // Int. J. Obes. Relat. Metab. Disord. - 2002. - Vol. 26, № 5. - P. 633-639.

121. Interactive effects between polymorphisms in the beta-adrenergic receptors and longitudinal changes in obesity / D.L. Ellsworth, S.A. Coady, W. Chen [et al.] // Obes. Res. - 2005. - Vol. 13, № 3. - Р. 519-526.

122. Максимов В.Н. Связь наследственной отягощенности и полиморфизма некоторых генов-кандидатов с сердечно-сосудистыми заболеваниями и их факторами риска в городской популяции Западной Сибири: дисс. на соискание уч. степени доктора мед. наук: спец. 14.00.06 "Кардиология" / Максимов Владимир Николаевич; Научно-исследовательский институт терапии, Сибирское отделение Российской академии медицинских наук. - Новосибирск. - 2007. - 198 с.

123. Influence of lipoprotein lipase gene Ser447Stop and beta1-adrenergic receptor gene Arg389Gly polymorphisms and their interaction on obesity from childchood to adulthoot: the Bogalusa Heart Study / S. Li, W. Chen, S.R. Srinivasan [et al.] // Int. J. Obes. (Lond). - 2006. - Vol. 30, № 8. - Р. 1183-1188.

124. Studies of associations between the Arg389Gly polymorphism of the beta1-adrenergic receptor gene (ADRв1) and hypertension and obesity in 7677 Danish white subjects / A.P. Gjesing, G. Andersen, A. Albrechtsen [et al.] // Diabet. Med. - 2007. - Vol. 24, № 4. - P. 392-397.

125. The Arg389Gly в1-adrenergic receptor gene polymorphism and human fat cell lipolysis / M. Ryden, J. Hoffstedt, P. Eriksson [et al.] // Int. J. Obes. - 2001. - № 25. - P. 1599-1603.

126. Association of ADRв1 and UCP3 gene polymorphisms with insulin sensitivity but not obesity / S. Mottagui-Tabar, J. Hoffstedt, A.J. Brookes [et al.] // Horm. Res. - 2008. - Vol. 69, № 1. - Р. 31-36.

127. Linne Y. Beta1-adrenoreceptor gene polymorphism predicts long-term changes in body weight / Y. Linne, J. Dahlman, J. Hoffstedt // Int. J. Obes. (Lond). - 2005. - Vol. 29, № 5. - Р. 458-462.

128. The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome / S. Hahn, U.H. Frey, W. Siffert [et al.] // Eur. J. Endocrinol. - 2006. - № 155. - P. 763-770.

129. G protein polymorphisms do not predict weight loss and improvement of hypertension in severely obese patients / N. Potoczna, M. Wertli, R. Steffen [et al.] // J. Gastrointest. Surg. - 2004. - № 8. - P. 862-868.

130. Agabiti-Rosei E. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues / E. Agabiti-Rosei, M.L. Muiesan // Blood Pressure. - 2001. - Vol. 10, № 5-6. - P. 288-298.

131. Berkin K.E. Essential hypertension: the heart and hypertension / K.E. Berkin, S.G. Ball // Hypertension. - 2001. - № 86. - P. 467-475.

132. Association of electrocardiographic left ventricular hypertrophy with incident cardiovascular disease in japanese older hypertensive patients [Електронний ресурс] / E.S. Edison, Y. Yano, S. Hoshide [et al.] // Am. J. Hypertens. - 2014. - № 29. - Режим доступу до журналу: http://www.ncbi.nlm.nih.gov/pubmed/25267736 - Назва з екрану.

133. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study / M.H. Drazner, D.L. Dries, R.M. Peshock [et al.] // Hypertension. - 2005. - № 46. - P. 124-129.

134. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study / G. Simone, V. Palmieri, J.N. Bella [et al.] // J. Hypertens. - 2002. - № 20. - P. 323-331.

135. Determinants of left ventricular hypertrophy in hypertensive patients: identification of high-risk patients by metabolic, vascular, and inflammatory risk factors / M. Peer, M. Boaz, M. Zipora [et al.] // Int. J. Angiol. - 2013. - № 22(4). - P. 223-228.

136. Hunter J.J. Signaling Pathways for Cardiac Hypertrophy and Failure / J.J. Hunter, K.R. Chien // New. Engl. J. Med. - 1999. - Vol. 341, № 17. - P. 1276-1283.

137. Vasan R.S. Cardiac function and obesity/ R.S. Vasan // Heart. - 2003. - № 89. - P. 1127-1129.

138. Left ventricular hypertrophy in severe obesity. Interaction among blood pressure, nocturnal hypoxemia, and body mass / E. Avelar, T.V. Cloward, J.M. Walker [et al.] // Hypertension. - 2007. - № 49. - P. 34-41.

139. Independent influence of overweight and obesity on the regression of left ventricular hypertrophy in hypertensive patients: a meta-analysis / K. Zhang, F. Huang, J. Chen [et al.] // Medicine (Baltimore). - 2014. - № 93(25). - P. 130-163.

140. Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies / C. Cuspidi, M. Rescaldani, C. Sala [et al.] // J. Hypertens. - 2014. - № 32(1). - P. 16-25.

141. De Simone G. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy. The LIFE Study / G. De Simone, K. Wachtell, V. Palmieri // Circulation. - 2005. - № 111. - P. 1924-1931.

142. Karpe F. Monitoring adipose tissue blood flow in man: a comparison between the (133) xenon washout method and microdialysis / F. Karpe, B.A. Fielding, V. Ilic // Int. J. Obes. Relat. Metab. Disord. - 2002. - № 26. - P. 1-5.

143. Relations of stroke volume and cardiac output to body composition: the strong heart study / T. Collis, R.B. Devereux, M.J. Roman [et al.] // Circulation. - 2001. - № 103. - P. 820-825.

144. The impact of obesity on the left ventricle. Multi-Ethnic Study of Atherosclerosis (MESA) / E.B. Turkbey, R.L. McClelland, R.A. Kronmal [et al.] // J. Am. Coll. Cardiol. Img. - 2010. - № 3. - P. 266-274.

145. Effects of insulin on left ventricular function during dynamic exercise in overweight and obese subjects / F.C. Sasso, O. Carbonara, R. Nasti [et al.] // Eur. Heart J. - 2005. - № 26. - P. 1205-1212.

146. Harmancey R. Adaptation and maladaptation of the heart in obesity / R. Harmancey, C.R. Wilson, H. Taegtmeyer // Hypertension. - 2008. - Vol. 52(2). - P. 181-187.

147. Simone de G. Morbid obesity and left ventricular geometry / G. Simone // Hypertension. - 2007. - Vol. 49(1). - P. 7-9.

148. Ковалева О.Н. Влияние избыточной массы тела, ожирения и абдоминального типа распределения жировой ткани на формирование гипертрофии левого желудочка у пациентов с артериальной гипертензией [Електронний ресурс] / О.Н. Ковалева, Д.И. Сорокин, Т.В. Ащеулова // Український кардіологічний журнал. - 2009. - № 1. - Режим доступу до журналу: http://www.ukrcardio.org/journal.php/article/347. - Назва з екрану.

149. Ковалева О.Н. Избыточная масса тела, ожирение и масса миокарда левого желудочка у гипертензивных пациентов / О.Н. Ковалева, Д.И. Сорокин // Ліки України. - 2008. - № 9. - С. 64-66.

Размещено на Allbest.ru